cyclopentolate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 757 | 512-15-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 31, 1974 | FDA | ALCON LABS INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Corneal oedema | 126.53 | 47.48 | 22 | 1084 | 1471 | 63486445 |
| Toxic anterior segment syndrome | 96.82 | 47.48 | 18 | 1088 | 1753 | 63486163 |
| Keratopathy | 93.75 | 47.48 | 15 | 1091 | 601 | 63487315 |
| Corneal epithelium defect | 86.65 | 47.48 | 13 | 1093 | 339 | 63487577 |
| Anterior chamber cell | 81.00 | 47.48 | 13 | 1093 | 531 | 63487385 |
| Punctate keratitis | 72.21 | 47.48 | 12 | 1094 | 609 | 63487307 |
| Visual acuity reduced | 55.86 | 47.48 | 19 | 1087 | 21807 | 63466109 |
| Hypopyon | 50.08 | 47.48 | 9 | 1097 | 723 | 63487193 |
| Floppy iris syndrome | 49.72 | 47.48 | 7 | 1099 | 115 | 63487801 |
| Mydriasis | 49.46 | 47.48 | 15 | 1091 | 11941 | 63475975 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Mydriasis | 56.27 | 47.16 | 15 | 624 | 7222 | 34949070 |
| Toxic anterior segment syndrome | 51.58 | 47.16 | 10 | 629 | 1159 | 34955133 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Corneal oedema | 139.71 | 38.17 | 27 | 1701 | 2593 | 79740067 |
| Toxic anterior segment syndrome | 138.27 | 38.17 | 27 | 1701 | 2737 | 79739923 |
| Keratopathy | 133.35 | 38.17 | 23 | 1705 | 1171 | 79741489 |
| Corneal epithelium defect | 123.28 | 38.17 | 20 | 1708 | 699 | 79741961 |
| Anterior chamber cell | 97.30 | 38.17 | 17 | 1711 | 932 | 79741728 |
| Punctate keratitis | 89.99 | 38.17 | 16 | 1712 | 970 | 79741690 |
| Mydriasis | 88.54 | 38.17 | 27 | 1701 | 17616 | 79725044 |
| Visual acuity reduced | 78.72 | 38.17 | 28 | 1700 | 29441 | 79713219 |
| Eye pain | 72.08 | 38.17 | 28 | 1700 | 37550 | 79705110 |
| Corneal opacity | 69.97 | 38.17 | 13 | 1715 | 1007 | 79741653 |
| Endophthalmitis | 55.39 | 38.17 | 15 | 1713 | 6413 | 79736247 |
| Intraocular pressure increased | 54.43 | 38.17 | 16 | 1712 | 9189 | 79733471 |
| Ocular hyperaemia | 50.48 | 38.17 | 20 | 1708 | 28186 | 79714474 |
| Hypopyon | 50.07 | 38.17 | 10 | 1718 | 1132 | 79741528 |
| Vision blurred | 49.64 | 38.17 | 30 | 1698 | 105868 | 79636792 |
| Iridocyclitis | 43.24 | 38.17 | 11 | 1717 | 3693 | 79738967 |
| Eye irritation | 41.72 | 38.17 | 16 | 1712 | 20665 | 79721995 |
| Foreign body sensation in eyes | 38.41 | 38.17 | 9 | 1719 | 2148 | 79740512 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | S01FA04 | SENSORY ORGANS OPHTHALMOLOGICALS MYDRIATICS AND CYCLOPLEGICS Anticholinergics |
| ATC | S01FA54 | SENSORY ORGANS OPHTHALMOLOGICALS MYDRIATICS AND CYCLOPLEGICS Anticholinergics |
| CHEBI has role | CHEBI:33295 | diagnostic aid |
| CHEBI has role | CHEBI:48876 | muscarinic antagonists |
| CHEBI has role | CHEBI:50370 | parasympatholytics |
| CHEBI has role | CHEBI:50513 | mydriatics |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018680 | Cholinergic Antagonists |
| MeSH PA | D018727 | Muscarinic Antagonists |
| MeSH PA | D009184 | Mydriatics |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D010276 | Parasympatholytics |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Dilated pupil | indication | 37125009 | |
| Cycloplegia | indication | 68158006 | DOID:10033 |
| Perioperative Mydriasis | indication | ||
| Uveitis | off-label use | 128473001 | DOID:13141 |
| Prevention of Posterior Synechiae | off-label use | ||
| Brain damage | contraindication | 2470005 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Arteriosclerotic vascular disease | contraindication | 72092001 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Spastic paralysis | contraindication | 78403003 | |
| Arterial aneurysm | contraindication | 233981004 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Disorder of coronary artery | contraindication | 414024009 | |
| Predisposition to Glaucoma | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.23 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019700 | VUID |
| N0000147792 | NUI |
| D01002 | KEGG_DRUG |
| 5870-29-1 | SECONDARY_CAS_RN |
| 106029 | RXNORM |
| 4018593 | VANDF |
| 4019700 | VANDF |
| C0010582 | UMLSCUI |
| CHEBI:4024 | CHEBI |
| CHEMBL1201338 | ChEMBL_ID |
| DB00979 | DRUGBANK_ID |
| CHEMBL1200473 | ChEMBL_ID |
| D003519 | MESH_DESCRIPTOR_UI |
| 2905 | PUBCHEM_CID |
| 7153 | IUPHAR_LIGAND_ID |
| 266 | INN_ID |
| I76F4SHP7J | UNII |
| 225 | MMSL |
| 242 | MMSL |
| 39891 | MMSL |
| 4518 | MMSL |
| 001752 | NDDF |
| 004703 | NDDF |
| 372869004 | SNOMEDCT_US |
| 8348002 | SNOMEDCT_US |
| 83534009 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cyclomydril | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0065-0359 | SOLUTION/ DROPS | 2 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclomydril | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0065-0359 | SOLUTION/ DROPS | 2 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclogyl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0065-0395 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclogyl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0065-0395 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclogyl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0065-0396 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclogyl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0065-0396 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclogyl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0065-0397 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclogyl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0065-0397 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-096 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 12 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-097 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-097 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-097 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-100 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-100 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-100 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 20 sections |
| AK-PENTOLATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-883 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 19 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-735 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-735 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-013 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 21 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3234 | SOLUTION | 10 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3874 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4697 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 21 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61314-396 | SOLUTION | 10 mg | OPHTHALMIC | ANDA | 20 sections |
| Cyclopentolate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61314-396 | SOLUTION | 10 mg | OPHTHALMIC | ANDA | 20 sections |